The assessment of interchangeability (prescribability and switchability) is one of the debatable topics in the generic drug industry. Currently, the question is whether we have an adequate assessment system for the evaluation of generic drug products. The objective of the study is to assess the comparative oral bioavailability of Itraconazole capsule 100mg after administering single dose to adult, healthy, human subjects in fasted state by different bioequivalence approaches like average bioequivalence (ABE), population bioequivalence (PBE) and individual bioequivalence (IBE) and to monitor the safety of study subjects. An open-label, balanced, randomized, two-treatment, twosequence, four-period, crossover, single-dose comparative oral bioavailability study was conducted in sixteen healthy, adult, human subjects in a fasted state. Test formulation, Itraconazole capsule 100mg, and reference formulation, SPORANOX ® (Itraconazole) capsule 100mg, were administered in a fasted state. The test formulation, Itraconazole capsule 100mg, showed bioinequivalent against reference SPORANOX ® (Itraconazole) capsule 100mg in study subjects under a fasted state. Also, the test formulation exhibited a similar safety and tolerability pro ile compared to the reference formulation.
Itraconazole, average bioequivalence, population bioequivalence, individual bioequivalence, fasted state ABSTRACT The assessment of interchangeability (prescribability and switchability) is one of the debatable topics in the generic drug industry. Currently, the question is whether we have an adequate assessment system for the evaluation of generic drug products. The objective of the study is to assess the comparative oral bioavailability of Itraconazole capsule 100mg after administering single dose to adult, healthy, human subjects in fasted state by different bioequivalence approaches like average bioequivalence (ABE), population bioequivalence (PBE) and individual bioequivalence (IBE) and to monitor the safety of study subjects. An open-label, balanced, randomized, two-treatment, twosequence, four-period, crossover, single-dose comparative oral bioavailability study was conducted in sixteen healthy, adult, human subjects in a fasted state. Test formulation, Itraconazole capsule 100mg, and reference formulation, SPORANOX ® (Itraconazole) capsule 100mg, were administered in a fasted state. The test formulation, Itraconazole capsule 100mg, showed bioinequivalent against reference SPORANOX ® (Itraconazole) capsule 100mg in study subjects under a fasted state. Also, the test formulation exhibited a similar safety and tolerability pro ile compared to the reference formulation. There was no report of serious adverse events (SAEs) and deaths in the study. The test formulation was found to be bio-inequivalent to reference formulation in the study subjects under a fasted state by estimating different bioequivalence approaches like average bioequivalence, population bioequivalence, and individual bioequivalence.
INTRODUCTION
The generic drug products are very vital for the treatment of patients. They have the advantage of the same therapeutic bene it as the innovator product with a substantial reduction in the cost. Now the question arises about how the generic drug product can be interchanged (prescribability and switch-ability) with the innovator product/ standard drug and how this gets assessed. In general, the generic product and the innovator product are assessed in a comparative bioavailability study by the average bioequivalence (ABE) evaluation method. In the ABE approach, the 90% con idence interval of the relative mean (Geometric mean) of the test formulations with that of reference formulation for Lntransformed transformed pharmacokinetic parameters (C max and AUCs) should be within 80.00% to 125.00% for a generic product to establish bioequivalence. When the drug which are highly variable in nature and narrow therapeutic index drug are dealt by ABE approach, the typical 80.00% to 125.00% con idence limits are allowed to expand or narrowed down based on the characteristic of the drug products. These modi ications in bioequivalence assessment raise the concern of whether ABE assessment is the right tool for the evaluation and whether this method adequately addresses interchangeability. ABE method considers only population mean for the assessment, whereas in the case of population bioequivalence (PBE) assessment, it considers inter-subject variability along with population mean, and individual bioequivalence (IBE) approach consider within-subject, and subject-byformulation variances along with population mean for the assessment. Hence PBE approach addresses the prescribability, and the IBE approach addresses switchability (Micheal and Balamurali, 2015) .
In order to understand the study outcome by applying the different bioequivalence assessment approaches in a clinical pharmacokinetic study, a model study with The chemical structure of Itraconazole is given in Figure 1 .
Pharmacokinetic pro iles of Itraconazole
C max − within 2 to 5 hours Absolute oral bioavailability -55%
Steady State attainment -within about 15 days
Terminal half-life -16 to 28 hours after a single dose and increases to 34 to 42 hours with repeated dosing (Sporanox ® PIL, 2018; Sporanox SPC, 2013; Pr Sporanox ® , 2019) .
MATERIALS AND METHODS

Ethical considerations
The study was started only after receiving an approval from the Institutional ethics committee (IEC), and from each subject, written informed consent was obtained. The study procedure was explained to the subjects in their respective native languages. The study was conducted as per the Good Clinical Practices, Declaration of Helsinki, and applicable requirements of principles of Good Laboratory Practices (WHO, 2009; OECD, 1977; ICMR, 2017) .
Study design
This was a balanced, randomized, open-label, twosequence, single-dose, two-treatment, four-period, fully replicate crossover comparative oral bioavailability study. As it's a complete replicated design Water intake -restricted at least from 1 hour before dosing until 2 hours post-dosing (except for water used for drug administration).
Posture restriction -remained seated for 4 hours post-dose & thereafter, to ambulate freely Any prescription medications -prohibited within 14days prior to dosing and throughout the study Over the counter (OTC) products, herbal medications -prohibited within 7 days prior to dosing and throughout the study
The study drug was administered with 240mL of water in each period. The dosing activities were monitored by the trained study team, and the dos-ing compliance was ensured.
In each period, 22 venous blood samples were collected at 0.0, 1.0, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 48.0, 72.0, 96.0 and 120.0 hours post-dose in labeled K 3 EDTA vacutainers for the evaluation of pharmacokinetic parameters. The pre-dose sample was collected within 1 hour before drug administration. The samples were centrifuged to separate the plasma at 3000rpm for a period of ifteen minutes at 4 • C. After separation of plasma, they were transferred in labelled tubes, which were collected in duplicate and stored at -20º± 10ºC in a deep freezer at the clinical site. Till the study subjects' samples were shifted to bioanalytical laboratories; they were kept in the clinical site.
Study population
Healthy subjects of age between 18 and 45 years (both inclusive)
2. BMI between 18.5 and 24.9 in kg/ m2
The subjects were chosen on the outcome of laboratory evaluations during screening, clinical examination, medical history, chest X-ray, and ECG recordings. For the reason of numerous socio-cultural circumstances, a female subject could not be convinced to stay at the clinical facility. Also, generally, females in a country like India are likely to have lesser hemoglobin levels. Further, the drug under investigation is not recognized to have a gender-speci ic pharmacokinetic pro ile. Therefore, the study was conducted by enrolling male subjects. The study subjects were chosen based on their inclusion and exclusion eligibility criteria. This study was conducted according to requirements of applicable regulatory agencies (E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1), 2018; Helsinki, 2008; bioanalytical method validation, 2018).
The study protocol and informed consent documents were submitted for an independent ethics committee (IEC) review and approval. Subjects were enrolled into the study only upon receipt of IEC approval.
Safety
Safety and tolerability of test and reference formulation for the enrolled subjects were evaluated in the study by the following ways. 
Bioanalytic methods
The bioanalytical method (HPLC-MS/MS bioanalytical method) was validated as per the recommendation from the FDA (bioanalytical method validation, 2018). The assay was carried out at Jeevan Scienti ic Technology Limited, Hyderabad, which was speci ic for the determination of Itraconazole.
Pharmacokinetic analysis
The following pharmacokinetic parameters were estimated for Itraconazole using a non-compartmental model analysis by using 
Statistical analysis
Statistical analyses were performed on the pharmacokinetic parameters using the General Linear Models Procedure (PROC GLM) of SAS Software (SAS Institute, Cary, NC). The model tests for treatment effects in the parameter means at an alpha level of 0.05. The parameters: T max , K el , and THalf were analyzed statistically using the non-transformed data. The natural log-transformed parameters: LNAUC 0−t , LNAUC 0−∞ , and LNC max were also analyzed. Tests were performed to analyze for statistically signi icant differences in the pharmacokinetic parameters and to determine the test to reference ratios of the pharmacokinetic parameters using Least Squares Means. Ninety (90%) percent con idence intervals were constructed using the two one-sided tests procedure to assess average bioequivalence between the two formulations. The primary pharmacokinetic variables for the assessment of bioequivalence were C max , AUC 0−t, and AUC 0−∞ . Statistical analysis of primary pharmacokinetic parameters C max , AUC 0−t, and AUC 0−∞ of Itraconazole was carried out using average bioequivalence, population bioequivalence, and individual bioequivalence approaches.
RESULTS AND DISCUSSION
Study subjects' demographic data
A total of 13 study subjects were enrolled into the study, and their demographic characteristics were comparable and presented in Table 1 .
Pharmacokinetic assessment
The mean plasma concentrations of a single dose of test formulation, Itraconazole capsule 100mg, and the standard formulation, (Sporanox ® PIL, 2018) (Itraconazole) capsule 100mg concentrations in a fasted state is presented in Figure 2 .
The pharmacokinetic parameters of a single dose of test formulation, Itraconazole capsule 100mg, and the standard formulation, (Sporanox ® PIL, 2018) (Itraconazole) capsule 100mg concentrations in a fasted state is presented in Table 2 .
Bioequivalence Assessment
The bioequivalence summary of a single dose of test formulation, Itraconazole capsule 100mg, and the standard formulation, (Sporanox ® PIL, 2018) (Itraconazole) capsule 100mg concentrations in a fasted state is presented in Table 3 .
Safety and tolerability pro ile
In total, 13 subjects received the investigational drugs in all the periods. Both the formulations (test and reference) were well tolerated. There were no deaths reported during the study. The safety pro ile of test Itraconazole capsule 100mg was found comparable to the standard drug (Sporanox ® PIL, 2018)(Itraconazole) capsule 100mg in a fasted state.
Though there has been a signi icant improvement in pharmaceutical research, the change is inevitable. Generic drugs play a signi icant role in treating patients all across the globe. The signi icant advantages of generic drugs are lower cost and providing the same ef icacy as innovator products. ABE approach is the gold standard bioequivalence evaluation method. Whether the drug belongs to a highly variable drug category or a narrow therapeutic index drug category, the same ABE approach is used for the evaluation, and the con idence limit is adjusted to make sure that the particular category of drug is evaluated as applicable. If the drug of interest for the evaluation is a highly variable drug category, 90% con idence internal will be applied, and the con idence limit will be widened. If the drug of interest for the evaluation is a narrow therapeutic index drug category, 90% con idence internal will be applied, and the con idence limit will be tightened. Though there have been numerous changes in the usage of the ABE approach, there were many discussions and doubts about using this approach for the narrow therapeutic index drug category and highly variable drug category. Then the alternative approaches like PBE and IBE approaches emerge (Zariffa et al., 2001; Endrenyi and Midha, 1998; Tothfalusi and Endrenyi, 2003; Wijnand, 2003; Dragojevic-Simic et al., 2017) .
From the available literatures, it is very well established that itraconazole has high intra-subject variability. Due to its high intra-subject variability, the available studies were conducted by partial/ complete replicate design (SBOA, 2010; Suarez-Kurtz et al., 1999; Dragojević-Simić et al., 2018) .
This clinical pharmacokinetic study was undertaken to assess the comparative oral bioavailability of test formulation, Itraconazole capsule 100mg against the standard formulation, (Sporanox ® PIL, 2018) (Itraconazole) capsule 100mg in a fasted state. In this study, the study outcomes were assessed by ABE approach along with PBE and IBE approaches. From the mean plasma concentration of test Itraconazole capsule 100mg, it was found to be not comparable to the standard drug (Sporanox ® PIL, 2018) (Itraconazole) capsule 100mg. Form the mean plasma drug concentration. It is quite evident that the test formulation release was slower than the reference formulation, and the same was observed with the pharmacokinetic parameters also. From the bioequivalence summary data, it is very clear that the test formulation is bio-inequivalent to the reference formulation. All the bioequivalence approaches assessment shown the same outcome. There was no death, and serious adverse events (SAEs) reported in the study. Both the test and reference formulation exhibited comparable safety and tolerability pro iles.
The objective of this clinical pharmacokinetic study was to understand the test formulation behavior and not to prove bioequivalence. Moreover, this was a pilot study. Based on the study outcome, it was quite apparent that the used test product must undergo re-development to meet bioequivalence with the standard drug.
CONCLUSIONS
It is apparent from the study outcome that test formulation is bio-inequivalent to the reference formulation by the ABE approach, and the same results were observed by evaluating the PBE approach and IBE approach. The primary pharmacokinetic parameters C max , AUC 0−t, and AUC 0−∞ were failing in ABE method, and AUC 0−t , AUC 0−∞ were passing though C max was failing in PBE and IBE method. Certainly, the study outcome clearly communicates that the study outcome differs in different bioequivalence approach evaluation as the considerations for the approaches are different.
